Literature DB >> 24578158

Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer.

Dar-Ren Chen1, Chun-Yi Chuang, Buor-Chang Wu, Shun-Fa Yang, Yu-Hsien Peng, Hsiu-Ting Tsai.   

Abstract

BACKGROUND: Genetic variants are reported to play an important role in the susceptibility of breast cancer. Ribonucleotide reductase 1 (RRM1) is suggested to play an essential role in the regulation of cancer development. The purpose of this study was to identify novel gene polymorphisms of RRM1 -756T>C and RRM1 -269 C>A specific to patients with breast cancer and healthy controls.
METHODS: A total of 833 subjects, including 321 healthy controls and 512 patients with breast cancer, were recruited in this study. Allelic discrimination of RRM1 -756T>C (rs11030919) and RRM1 -269C>A (rs12806698) polymorphisms of the RRM1 gene was assessed with the real-time polymerase chain reaction.
RESULTS: The adjusted odds ratios and 95% confidence intervals were 1.20 (0.71-2.04) and 1.10 (0.65-1.86) to have breast cancer among individuals with CC alleles of RRM1 -756T>C and individuals with AA alleles of RRM1 -269C>A gene polymorphism, respectively, compared to individuals having wild type of RRM1 gene polymorphisms. Also, there was no significant genetic interaction effect on the susceptibility of breast cancer and nonassociation between genetic polymorphisms and clinical statuses of breast cancer.
CONCLUSION: Gene polymorphisms of RRM1 -756T>C and RRM1 -269C>A may be not an important factor for the susceptibility of breast cancer.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; ribonucleotide reductase 1; single nucleotide polymorphism

Mesh:

Substances:

Year:  2014        PMID: 24578158      PMCID: PMC6807465          DOI: 10.1002/jcla.21682

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  29 in total

1.  Germline variants of base excision repair genes and breast cancer: A polymorphism in DNA polymerase gamma modifies gene expression and breast cancer risk.

Authors:  Odilia Popanda; Petra Seibold; Ivaylo Nikolov; Christopher C Oakes; Barbara Burwinkel; Sebastian Hausmann; Dieter Flesch-Janys; Christoph Plass; Jenny Chang-Claude; Peter Schmezer
Journal:  Int J Cancer       Date:  2012-06-26       Impact factor: 7.396

2.  Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

Authors:  Ashish Gautam; Gerold Bepler
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.

Authors:  Anna Bergamaschi; Young H Kim; Pei Wang; Therese Sørlie; Tina Hernandez-Boussard; Per E Lonning; Robert Tibshirani; Anne-Lise Børresen-Dale; Jonathan R Pollack
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

4.  Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.

Authors:  W Y Huang; B Newman; R C Millikan; M J Schell; B S Hulka; P G Moorman
Journal:  Am J Epidemiol       Date:  2000-04-01       Impact factor: 4.897

5.  Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells.

Authors:  Yung-Luen Yu; Kuo-Jung Su; Cheng-Jueng Chen; Chyou-Wei Wei; Ching-Ju Lin; Giou-Teng Yiang; Shinn-Zong Lin; Horng-Jyh Harn; Yi-Lin Sophia Chen
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

6.  In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Authors:  G Metro; Z Zheng; A Fabi; M Schell; B Antoniani; M Mottolese; A N Monteiro; P Vici; S Lara Rivera; D Boulware; F Cognetti; G Bepler
Journal:  Cancer Invest       Date:  2010-02       Impact factor: 2.176

7.  Interaction of MTHFR C677T and A1298C, and MTR A2756G gene polymorphisms in breast cancer risk in a population in Northeast Brazil.

Authors:  Rita de Cássia Carvalho Barbosa; Débora Menezes da Costa; Denise Ellen Francelino Cordeiro; Ana Patricia Freitas Vieira; Silvia Helena Barem Rabenhorst
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

8.  Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Authors:  Hirotaka Iwase; Junichi Kurebayashi; Hitoshi Tsuda; Tomohiko Ohta; Masafumi Kurosumi; Kazuaki Miyamoto; Yutaka Yamamoto; Takuji Iwase
Journal:  Breast Cancer       Date:  2009-05-23       Impact factor: 4.239

9.  Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.

Authors:  Luis A Fernández-Morales; Miquel A Seguí; Xavier Andreu; Elsa Dalmau; Amparo Sáez; Carles Pericay; Cristina Santos; Jesús Montesinos; Enrique Gallardo; Angels Arcusa; Eugeni Saigí
Journal:  Clin Breast Cancer       Date:  2007-04       Impact factor: 3.225

10.  Association between the c.*229C>T polymorphism of the topoisomerase IIβ binding protein 1 (TopBP1) gene and breast cancer.

Authors:  Ewa Forma; Ewa Brzeziańska; Anna Krześlak; Grażyna Chwatko; Paweł Jóźwiak; Agnieszka Szymczyk; Beata Smolarz; Hanna Romanowicz-Makowska; Waldemar Różański; Magdalena Bryś
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.